Novo Nordisk Pipeline

Goals

To develop an informed business pitch by digging into Novo Nordisk’s drug/treatment pipeline and identifying the advances in its new drugs. The current objective is to provide details (overview and treatment) on 8-10 of Novo Nordisk’s drugs/treatments launched in 2019.

Early Findings

Confirmed New Launches

  • Rybelsus (semaglutide; tablets 7 mg or 14 mg) — The drug is for treating adults with type 2 diabetes; it is the “first and only glucagon-like peptide-1 (GLP-1) analog in a pill and a new option for adults with type 2 diabetes who are not achieving their A1C goal with current antidiabetic treatment.”
  • *Victoza — While this drug had originally launched in the US in 2010, in 2019 it was approved for pediatric patients 10 yo and older with type 2 diabetes.
  • *Xultophy — In September 2019, the drug was launched in Japan. The drug is used to treat type 2 diabetes. Active substances are insulin degludec and liraglutide.
  • *Ryzodeg — Was recently approved in China, and there were hopes (according to a call transcript) to launch it in the country before the end of 2019. Ryzodeg, an injection, is used to treat diabetes in patients 2 years old and up.
*Please note that several of the drugs were previously launched but are listed here because they were newly launched in 2019 in countries that had not previously approved the drug or the drug’s sales had experienced a noted surge in launches within new countries.

Launches Needing Confirmation

In addition to this public search, we scanned our proprietary research database of over 1 million sources and were unable to find any specific research reports that address your goals.

Proposed next steps:

You need to be the project owner to select a next step.